Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,829 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vaccine Safety Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers

NCT01984983
View directory record Official record
Conditions
Venezuelan Equine Encephalitis Virus Infection
Interventions
Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate, 0.9% saline placebo
Biological · Other
Lead sponsor
Ichor Medical Systems Incorporated
Industry
Eligibility
18 Years to 49 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 2, 2026, 4:02 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine in Healthy Adults

NCT03051386
View directory record Official record
Conditions
Venezuelan Equine Encephalomyelitis Virus Disease
Interventions
VEE Vaccine
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 2, 2026, 4:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine

NCT00258882
View directory record Official record
Conditions
Pertussis
Interventions
Tetanus Toxoid, acellular pertussis, diphtheria toxoid
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
327,293 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
3
States / cities
Oakland, California • Aurora, Colorado • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 2, 2026, 4:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)

NCT04283461
View directory record Official record
Conditions
COVID-19, COVID-19 Immunisation
Interventions
mRNA-1273
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Decatur, Georgia • Bethesda, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 2, 2026, 4:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

NCT04228783
View directory record Official record
Conditions
Ebola
Interventions
Ad26.ZEBOV, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
974 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
7
States / cities
Mobile, Alabama • Tempe, Arizona • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 2, 2026, 4:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years

NCT06573281
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Investigational RSV vaccine 1, Investigational RSV vaccine 2, Investigational RSV vaccine 3, Investigational RSV vaccine 4, Investigational RSV vaccine 5, Investigational RSV vaccine 6, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
5
States / cities
Rolling Hills Estates, California • Atlanta, Georgia • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 2, 2026, 4:02 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Kidney Cancer

NCT00096629
View directory record Official record
Conditions
Kidney Cancer
Interventions
human prostate-specific membrane antigen plasmid DNA vaccine, mouse prostate-specific membrane antigen plasmid DNA vaccine
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 2, 2026, 4:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects

NCT05178901
View directory record Official record
Conditions
Nipah Virus Infection
Interventions
PHV02, Placebo
Biological · Other
Lead sponsor
Public Health Vaccines LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 2, 2026, 4:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years

NCT01706367
View directory record Official record
Conditions
Clostridium Difficile Associated Disease
Interventions
C. difficile vaccine, C. difficile vaccine +adjuvant
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Pembroke Pines, Florida • South Miami, Florida • Overland Park, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 2, 2026, 4:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection

NCT00120081
View directory record Official record
Conditions
Hookworm Infection
Interventions
Na-ASP-2/Alhydrogel Hookworm Vaccine, Saline placebo
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 2, 2026, 4:02 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation

NCT02388165
View directory record Official record
Conditions
Staphylococcal Vaccine
Interventions
Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
3,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
234
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 2, 2026, 4:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

NCT00000757
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1992
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 2, 2026, 4:02 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o.

NCT00216242
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (Fluviral), Saline placebo
Biological
Lead sponsor
ID Biomedical Corporation, Quebec
Industry
Eligibility
18 Years to 49 Years
Enrollment
7,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
43
States / cities
Sacramento, California • San Francisco, California • Denver, Colorado + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2006 · Synced Oct 2, 2026, 4:02 AM EDT
Terminated Phase 1 Interventional Results available

Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC

NCT03674827
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Triple-negative Breast Cancer
Interventions
PF-06936308
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
34
States / cities
Encinitas, California • La Jolla, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 2, 2026, 4:02 AM EDT
Completed Phase 1Phase 2 Interventional

Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer

NCT00050323
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Allogeneic DCs and Autologous RCC Tumor Derived Cells
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 2, 2026, 4:02 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)

NCT03349983
View directory record Official record
Conditions
Safety Issues
Interventions
MVA-BN-Brachyury/ FPV-Brachyury
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Oct 2, 2026, 4:02 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants

NCT02927873
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV (GSK3389245A) low dose formulation vaccine, RSV (GSK3389245A) middle dose formulation vaccine, RSV (GSK3389245A) high dose formulation vaccine, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 23 Months
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
6
States / cities
Anaheim, California • Aurora, Colorado • Topeka, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 2, 2026, 4:02 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People

NCT06821061
View directory record Official record
Conditions
Influenza, COVID-19 (Coronavirus Disease 2019)
Interventions
Investigational Influenza Vaccine, Investigational COVID-19 Vaccine, Investigational Influenza and COVID-19 Combination Vaccine, Licensed Influenza Vaccine 1, Licensed Influenza Vaccine 2, Licensed Influenza Vaccine 3, Licensed COVID-19 Vaccine
Biological · Combination Product
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
2,650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
31
States / cities
Anaheim, California • Lake Forest, California • Riverside, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 2, 2026, 4:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults

NCT03341754
View directory record Official record
Conditions
Malaria
Interventions
D/ChAd63-CA, D/ChAd63-CAT, Infectivity Control (IC) Group
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Bethesda, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 2, 2026, 4:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly

NCT00391053
View directory record Official record
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
High-Dose Inactivated, Split-Virion Influenza Vaccine, Inactivated, Split-Virion Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
3,851 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
28
States / cities
Mesa, Arizona • Phoenix, Arizona • Tempe, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 2, 2026, 4:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted

NCT03547245
View directory record Official record
Conditions
HIV/AIDS
Interventions
eOD-GT8 60mer + AS01B/ DPBS sucrose/IM, DPBS Sucrose
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Oct 2, 2026, 4:02 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Head and Neck Cancer

NCT00404339
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
mutant p53 peptide pulsed dendritic cell vaccine, tetanus toxoid helper peptide, adjuvant therapy
Biological · Procedure
Lead sponsor
Robert Ferris
Other
Eligibility
18 Years to 120 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 2, 2026, 4:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety of RIV4 Versus IIV4 in Pregnant Women

NCT03969641
View directory record Official record
Conditions
Safety, Adverse Event Following Immunisation, Birth Outcomes
Interventions
Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
384 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 2, 2026, 4:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine

NCT01290419
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV-F Particle Vaccine, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 2, 2026, 4:02 AM EDT